Along with these changes, NAFLD can lead to hepatic steatosis, NASH, hepatic cirrhosis, and hepatocellular carcinoma.95 In patients with T2DM, both glucose and lipid metabolisms are deteriorated, leading to the increase of plasma levels of low-density lipoprotein, and adversely reduction of high-density lipoprotein.96 In the case of NAFLD, the content of different serum transaminases is slightly raised with NAFLD and the administration of GLP-1R could decrease systemic transaminase levels via the promotion of hepatic lipid metabolism. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.